ID   RAF1_HUMAN              Reviewed;         648 AA.
AC   P04049; B0LPH8; B2R5N3; Q15278; Q9UC20;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1986, sequence version 1.
DT   02-NOV-2010, entry version 144.
DE   RecName: Full=RAF proto-oncogene serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Proto-oncogene c-RAF;
DE            Short=cRaf;
DE   AltName: Full=Raf-1;
GN   Name=RAF1; Synonyms=RAF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=86120351; PubMed=3003687; DOI=10.1093/nar/14.2.1009;
RA   Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A.,
RA   Young A.C., Rapp U.R.;
RT   "The complete coding sequence of the human raf oncogene and the
RT   corresponding structure of the c-raf-1 gene.";
RL   Nucleic Acids Res. 14:1009-1015(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-308.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648.
RX   MEDLINE=85295973; PubMed=2993863;
RA   Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.;
RT   "Structure and biological activity of human homologs of the raf/mil
RT   oncogene.";
RL   Mol. Cell. Biol. 5:1400-1407(1985).
RN   [7]
RP   PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269.
RX   MEDLINE=96069769; PubMed=7477354; DOI=10.1038/378307a0;
RA   Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.;
RT   "Phosphorylation of Raf by ceramide-activated protein kinase.";
RL   Nature 378:307-310(1995).
RN   [8]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   MEDLINE=91360260; PubMed=1886707;
RA   Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.;
RT   "An alternatively spliced c-mil/raf mRNA is predominantly expressed in
RT   chicken muscular tissues and conserved among vertebrate species.";
RL   Oncogene 6:1307-1311(1991).
RN   [9]
RP   PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621.
RX   MEDLINE=93352516; PubMed=8349614;
RA   Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.;
RT   "Identification of the major phosphorylation sites of the Raf-1
RT   kinase.";
RL   J. Biol. Chem. 268:17309-17316(1993).
RN   [10]
RP   INTERACTION WITH YWHAZ, AND FUNCTION.
RX   PubMed=9360956; DOI=10.1074/jbc.272.46.28882;
RA   Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y.,
RA   Morrice N., Moelling K., Aitken A.;
RT   "14-3-3 is phosphorylated by casein kinase I on residue 233.
RT   Phosphorylation at this site in vivo regulates Raf/14-3-3
RT   interaction.";
RL   J. Biol. Chem. 272:28882-28888(1997).
RN   [11]
RP   PHOSPHORYLATION.
RX   MEDLINE=99039505; PubMed=9823899; DOI=10.1038/24184;
RA   King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S.,
RA   Marshall M.S.;
RT   "The protein kinase Pak3 positively regulates Raf-1 activity through
RT   phosphorylation of serine 338.";
RL   Nature 396:180-183(1998).
RN   [12]
RP   ERRATUM.
RA   King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S.,
RA   Marshall M.S.;
RL   Nature 406:439-439(2000).
RN   [13]
RP   COMPETITION WITH RIN1.
RX   MEDLINE=21644479; PubMed=11784866;
RX   DOI=10.1128/MCB.22.13.4638-4651.2002;
RA   Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E.,
RA   Colicelli J.;
RT   "The RAS effector RIN1 directly competes with RAF and is regulated by
RT   14-3-3 proteins.";
RL   Mol. Cell. Biol. 22:916-926(2002).
RN   [14]
RP   PHOSPHORYLATION AT SER-259.
RX   PubMed=15047712; DOI=10.1074/jbc.M314192200;
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RT   "LGI1, a putative tumor metastasis suppressor gene, controls in vitro
RT   invasiveness and expression of matrix metalloproteinases in glioma
RT   cells through the ERK1/2 pathway.";
RL   J. Biol. Chem. 279:23151-23157(2004).
RN   [15]
RP   ERRATUM.
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RL   J. Biol. Chem. 282:2752-2752(2007).
RN   [16]
RP   INTERACTION WITH STK3, AND FUNCTION.
RX   PubMed=15618521; DOI=10.1126/science.1103233;
RA   O'Neill E., Rushworth L., Baccarini M., Kolch W.;
RT   "Role of the kinase MST2 in suppression of apoptosis by the proto-
RT   oncogene product Raf-1.";
RL   Science 306:2267-2270(2004).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294 AND SER-301, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND
RP   MRAS, PHOSPHORYLATION AT SER-259, AND MUTAGENESIS OF SER-259.
RX   PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027;
RA   Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M.,
RA   McCormick F.;
RT   "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic
RT   subunit of PP1 functions as an M-Ras effector to modulate Raf
RT   activity.";
RL   Mol. Cell 22:217-230(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-621, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=19007248; DOI=10.1021/ac801708p;
RA   Wang B., Malik R., Nigg E.A., Korner R.;
RT   "Evaluation of the low-specificity protease elastase for large-scale
RT   phosphoproteome analysis.";
RL   Anal. Chem. 80:9526-9533(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257 AND THR-258, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43; SER-244 AND SER-259,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289; SER-301 AND
RP   SER-612, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131.
RX   MEDLINE=95312074; PubMed=7791872; DOI=10.1038/375554a0;
RA   Nassar N., Horn G., Herrmann C., Scherer A., McCormick F.,
RA   Wittinghofer A.;
RT   "The 2.2 A crystal structure of the Ras-binding domain of the
RT   serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP
RT   analogue.";
RL   Nature 375:554-560(1995).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131.
RX   MEDLINE=96313130; PubMed=8756332; DOI=10.1038/nsb0896-723;
RA   Nassar N., Horn G., Herrmann C., Block C., Janknecht R.,
RA   Wittinghofer A.;
RT   "Ras/Rap effector specificity determined by charge reversal.";
RL   Nat. Struct. Biol. 3:723-729(1996).
RN   [29]
RP   STRUCTURE BY NMR OF 55-132.
RX   MEDLINE=95284022; PubMed=7766599; DOI=10.1021/bi00021a001;
RA   Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E.,
RA   Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.;
RT   "Solution structure of the Ras-binding domain of c-Raf-1 and
RT   identification of its Ras interaction surface.";
RL   Biochemistry 34:6911-6918(1995).
RN   [30]
RP   STRUCTURE BY NMR OF 136-187.
RX   MEDLINE=96323218; PubMed=8710867; DOI=10.1073/pnas.93.16.8312;
RA   Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M.,
RA   Campbell S.L.;
RT   "The solution structure of the Raf-1 cysteine-rich domain: a novel ras
RT   and phospholipid binding site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996).
RN   [31]
RP   VARIANTS NS5 SER-256; PHE-259; ARG-260; LEU-261; SER-261; ASN-486;
RP   GLY-486; ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC
RP   CARDIOMYOPATHY ILE-260, VARIANT LEOPARD SYNDROME-2 VAL-613, VARIANT
RP   NS5/LEOPARD SYNDROME-2 LEU-257, CHARACTERIZATION OF VARIANTS NS5
RP   SER-261; ASN-486 AND ILE-491, AND CHARACTERIZATION OF VARIANT LEOPARD
RP   SYNDROME-2 VAL-613.
RX   PubMed=17603483; DOI=10.1038/ng2073;
RA   Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K.,
RA   Martinelli S., Pogna E.A., Schackwitz W., Ustaszewska A.,
RA   Landstrom A., Bos J.M., Ommen S.R., Esposito G., Lepri F., Faul C.,
RA   Mundel P., Lopez Siguero J.P., Tenconi R., Selicorni A., Rossi C.,
RA   Mazzanti L., Torrente I., Marino B., Digilio M.C., Zampino G.,
RA   Ackerman M.J., Dallapiccola B., Tartaglia M., Gelb B.D.;
RT   "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes
RT   with hypertrophic cardiomyopathy.";
RL   Nat. Genet. 39:1007-1012(2007).
RN   [32]
RP   VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND
RP   CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263
RP   AND VAL-613.
RX   PubMed=17603482; DOI=10.1038/ng2078;
RA   Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R.,
RA   Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y.,
RA   Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J.,
RA   Higashinakagawa T., Matsuoka R.;
RT   "Germline gain-of-function mutations in RAF1 cause Noonan syndrome.";
RL   Nat. Genet. 39:1013-1017(2007).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Involved in the transduction of mitogenic signals from
CC       the cell membrane to the nucleus. Part of the Ras-dependent
CC       signaling pathway from receptors to the nucleus. Protects cells
CC       from apoptosis mediated by STK3.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Binds 2 zinc ions per subunit.
CC   -!- SUBUNIT: Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2
CC       and protein phosphatase 1 (PPP1CA, PPP1CB and PPP1CC). Interacts
CC       with Ras proteins; the interaction is antagonized by RIN1. Weakly
CC       interacts with RIT1 (By similarity). Interacts with STK3; the
CC       interaction inhibits its pro-apoptotic activity. Interacts (when
CC       phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-
CC       232').
CC   -!- INTERACTION:
CC       P15056:BRAF; NbExp=9; IntAct=EBI-365996, EBI-365980;
CC       P49368:CCT3; NbExp=3; IntAct=EBI-365996, EBI-356673;
CC       P30304:CDC25A; NbExp=1; IntAct=EBI-365996, EBI-747671;
CC       Q9UNS2:COPS3; NbExp=2; IntAct=EBI-365996, EBI-350590;
CC       P31327:CPS1; NbExp=2; IntAct=EBI-365996, EBI-536811;
CC       P01112:HRAS; NbExp=5; IntAct=EBI-365996, EBI-350145;
CC       P08238:HSP90AB1; NbExp=1; IntAct=EBI-365996, EBI-352572;
CC       P11021:HSPA5; NbExp=3; IntAct=EBI-365996, EBI-354921;
CC       Q9NVR2:INTS10; NbExp=2; IntAct=EBI-365996, EBI-536703;
CC       Q02750:MAP2K1; NbExp=1; IntAct=EBI-365996, EBI-492564;
CC       O43482:OIP5; NbExp=3; IntAct=EBI-365996, EBI-536879;
CC       Q13177:PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887;
CC       P14618:PKM2; NbExp=3; IntAct=EBI-365996, EBI-353408;
CC       P62834:RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414;
CC       P53805:RCAN1; NbExp=3; IntAct=EBI-365996, EBI-1541887;
CC       Q3ZCQ8:TIMM50; NbExp=3; IntAct=EBI-365996, EBI-355175;
CC       P31946:YWHAB; NbExp=6; IntAct=EBI-365996, EBI-359815;
CC       P61981:YWHAG; NbExp=1; IntAct=EBI-365996, EBI-359832;
CC       Q04917:YWHAH; NbExp=1; IntAct=EBI-365996, EBI-306940;
CC       P27348:YWHAQ; NbExp=1; IntAct=EBI-365996, EBI-359854;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-365996, EBI-347088;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=6C;
CC         IsoId=P04049-1; Sequence=Displayed;
CC       Name=2; Synonyms=1A;
CC         IsoId=P04049-2; Sequence=VSP_034649;
CC   -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant
CC       than isoform 2.
CC   -!- PTM: Phosphorylated upon DNA damage, probably by ATM or ATR.
CC       Phosphorylation at Thr-269 increases its kinase activity.
CC       Phosphorylation at Ser-259 induces the interaction with YWHAZ and
CC       inactivates kinase activity. Dephosphorylation of Ser-259 by the
CC       complex containing protein phosphatase 1, SHOC2 and M-Ras/MRAS
CC       relieves inactivation, leading to stimulate RAF1 activity.
CC   -!- DISEASE: Defects in RAF1 are the cause of Noonan syndrome type 5
CC       (NS5) [MIM:611553]. Noonan syndrome (NS) is a disorder
CC       characterized by dysmorphic facial features, short stature,
CC       hypertelorism, cardiac anomalies, deafness, motor delay, and a
CC       bleeding diathesis. It is a genetically heterogeneous and
CC       relatively common syndrome, with an estimated incidence of 1 in
CC       1000-2500 live births.
CC   -!- DISEASE: Defects in RAF1 are the cause of LEOPARD syndrome type 2
CC       (LEOPARD syndrome-2) [MIM:611554]. LEOPARD syndrome is an
CC       autosomal dominant disorder allelic with Noonan syndrome. The
CC       acronym LEOPARD stands for lentigines, electrocardiographic
CC       conduction abnormalities, ocular hypertelorism, pulmonic stenosis,
CC       abnormalities of genitalia, retardation of growth, and deafness.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. RAF subfamily.
CC   -!- SIMILARITY: Contains 1 phorbol-ester/DAG-type zinc finger.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 RBD (Ras-binding) domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/RAF1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/raf1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RAF1ID42032ch3p25.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03484; CAA27204.1; -; mRNA.
DR   EMBL; AY271661; AAP03432.1; -; Genomic_DNA.
DR   EMBL; AK312248; BAG35180.1; -; mRNA.
DR   EMBL; EU332868; ABY87557.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64134.1; -; Genomic_DNA.
DR   EMBL; BC018119; AAH18119.1; -; mRNA.
DR   EMBL; L00212; AAA60247.1; -; Genomic_DNA.
DR   EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA.
DR   EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   IPI; IPI00021786; -.
DR   IPI; IPI00900312; -.
DR   PIR; A00637; TVHUF6.
DR   PIR; S60341; S60341.
DR   RefSeq; NP_002871.1; -.
DR   UniGene; Hs.159130; -.
DR   PDB; 1C1Y; X-ray; 1.90 A; B=55-131.
DR   PDB; 1FAQ; NMR; -; A=136-187.
DR   PDB; 1FAR; NMR; -; A=136-187.
DR   PDB; 1GUA; X-ray; 2.00 A; B=51-131.
DR   PDB; 1RFA; NMR; -; A=55-132.
DR   PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264.
DR   PDB; 3IQJ; X-ray; 1.15 A; P=255-264.
DR   PDB; 3IQU; X-ray; 1.05 A; P=255-260.
DR   PDB; 3IQV; X-ray; 1.20 A; P=255-260.
DR   PDB; 3KUC; X-ray; 1.92 A; B=51-131.
DR   PDB; 3KUD; X-ray; 2.15 A; B=51-131.
DR   PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264.
DR   PDB; 3OMV; X-ray; 4.00 A; A/B=323-618.
DR   PDBsum; 1C1Y; -.
DR   PDBsum; 1FAQ; -.
DR   PDBsum; 1FAR; -.
DR   PDBsum; 1GUA; -.
DR   PDBsum; 1RFA; -.
DR   PDBsum; 3CU8; -.
DR   PDBsum; 3IQJ; -.
DR   PDBsum; 3IQU; -.
DR   PDBsum; 3IQV; -.
DR   PDBsum; 3KUC; -.
DR   PDBsum; 3KUD; -.
DR   PDBsum; 3NKX; -.
DR   PDBsum; 3OMV; -.
DR   ProteinModelPortal; P04049; -.
DR   SMR; P04049; 342-615.
DR   DisProt; DP00171; -.
DR   DIP; DIP-1048N; -.
DR   IntAct; P04049; 97.
DR   MINT; MINT-86694; -.
DR   STRING; P04049; -.
DR   PhosphoSite; P04049; -.
DR   PRIDE; P04049; -.
DR   Ensembl; ENST00000251849; ENSP00000251849; ENSG00000132155.
DR   GeneID; 5894; -.
DR   KEGG; hsa:5894; -.
DR   UCSC; uc003bxf.2; human.
DR   CTD; 5894; -.
DR   GeneCards; GC03M012600; -.
DR   H-InvDB; HIX0003068; -.
DR   HGNC; HGNC:9829; RAF1.
DR   HPA; CAB019291; -.
DR   HPA; HPA002640; -.
DR   MIM; 164760; gene.
DR   MIM; 611553; phenotype.
DR   MIM; 611554; phenotype.
DR   Orphanet; 500; LEOPARD syndrome.
DR   Orphanet; 648; Noonan syndrome.
DR   PharmGKB; PA142671136; -.
DR   eggNOG; prNOG06206; -.
DR   HOVERGEN; HBG001886; -.
DR   InParanoid; P04049; -.
DR   OMA; DGPSCIS; -.
DR   OrthoDB; EOG9QC3QR; -.
DR   PhylomeDB; P04049; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; bcr_5pathway; BCR signaling pathway.
DR   Pathway_Interaction_DB; ceramidepathway; Ceramide signaling pathway.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; cd8tcrdownstreampathway; Downstream signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; igf1_pathway; IGF1 pathway.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; p38_mk2pathway; p38 signaling mediated by MAPKAP kinases.
DR   Pathway_Interaction_DB; tcrraspathway; Ras signaling in the CD4+ TCR pathway.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   Pathway_Interaction_DB; mapktrkpathway; Trk receptor signaling mediated by the MAPK pathway.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_13685; Synaptic Transmission.
DR   Reactome; REACT_16888; Signaling by PDGF.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_9417; Signaling by EGFR.
DR   BindingDB; P04049; -.
DR   DrugBank; DB00398; Sorafenib.
DR   NextBio; 22930; -.
DR   PMAP-CutDB; P04049; -.
DR   ArrayExpress; P04049; -.
DR   Bgee; P04049; -.
DR   CleanEx; HS_RAF1; -.
DR   Genevestigator; P04049; -.
DR   GermOnline; ENSG00000132155; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0005057; F:receptor signaling protein activity; IEA:InterPro.
DR   GO; GO:0006915; P:apoptosis; TAS:ProtInc.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; TAS:ProtInc.
DR   GO; GO:0007265; P:Ras protein signal transduction; EXP:Reactome.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; Prot_Kinase_C-like_PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR003116; Raf-like_ras-bd.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF02196; RBD; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00455; RBD; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50898; RBD; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Kinase; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    648       RAF proto-oncogene serine/threonine-
FT                                protein kinase.
FT                                /FTId=PRO_0000086596.
FT   DOMAIN       56    131       RBD.
FT   DOMAIN      349    609       Protein kinase.
FT   ZN_FING     138    184       Phorbol-ester/DAG-type.
FT   NP_BIND     355    363       ATP (By similarity).
FT   ACT_SITE    468    468       Proton acceptor.
FT   METAL       139    139       Zinc 1.
FT   METAL       152    152       Zinc 2.
FT   METAL       155    155       Zinc 2.
FT   METAL       165    165       Zinc 1.
FT   METAL       168    168       Zinc 1.
FT   METAL       173    173       Zinc 2.
FT   METAL       176    176       Zinc 2.
FT   METAL       184    184       Zinc 1.
FT   BINDING     375    375       ATP (By similarity).
FT   MOD_RES      43     43       Phosphoserine.
FT   MOD_RES     244    244       Phosphoserine.
FT   MOD_RES     252    252       Phosphoserine.
FT   MOD_RES     257    257       Phosphoserine.
FT   MOD_RES     258    258       Phosphothreonine.
FT   MOD_RES     259    259       Phosphoserine; by PKC.
FT   MOD_RES     268    268       Phosphothreonine; by autocatalysis.
FT   MOD_RES     269    269       Phosphothreonine; by PKA.
FT   MOD_RES     289    289       Phosphoserine.
FT   MOD_RES     294    294       Phosphoserine.
FT   MOD_RES     301    301       Phosphoserine.
FT   MOD_RES     338    338       Phosphoserine; by PAK2 and PAK3.
FT   MOD_RES     499    499       Phosphoserine; by PKC.
FT   MOD_RES     612    612       Phosphoserine.
FT   MOD_RES     621    621       Phosphoserine.
FT   MOD_RES     642    642       Phosphoserine.
FT   VAR_SEQ     278    278       E -> ENNNLSASPRAWSRRFCLRGR (in isoform
FT                                2).
FT                                /FTId=VSP_034649.
FT   VARIANT     256    256       R -> S (in NS5).
FT                                /FTId=VAR_037807.
FT   VARIANT     257    257       S -> L (in NS5 and LEOPARD sndrome-2;
FT                                shows in vitro greater kinase activity
FT                                and enhanced ERK activation than wild-
FT                                type).
FT                                /FTId=VAR_037808.
FT   VARIANT     259    259       S -> A (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041037.
FT   VARIANT     259    259       S -> F (in NS5).
FT                                /FTId=VAR_037809.
FT   VARIANT     260    260       T -> I (in hypertrophic cardiomyopathy).
FT                                /FTId=VAR_037810.
FT   VARIANT     260    260       T -> R (in NS5).
FT                                /FTId=VAR_037811.
FT   VARIANT     261    261       P -> A (in NS5; shows in vitro greater
FT                                kinase activity and enhanced MAPK1
FT                                activation than wild-type).
FT                                /FTId=VAR_037812.
FT   VARIANT     261    261       P -> L (in NS5; shows greater kinase
FT                                activity and enhanced MAPK1 activation
FT                                than wild-type).
FT                                /FTId=VAR_037813.
FT   VARIANT     261    261       P -> S (in NS5; shows in vitro greater
FT                                kinase activity and enhanced MAPK1
FT                                activation than wild-type).
FT                                /FTId=VAR_037814.
FT   VARIANT     263    263       V -> A (in NS5; shows in vitro greater
FT                                kinase activity and enhanced MAPK1
FT                                activation than wild-type).
FT                                /FTId=VAR_037815.
FT   VARIANT     308    308       P -> L (in dbSNP:rs5746220).
FT                                /FTId=VAR_018840.
FT   VARIANT     335    335       Q -> H (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041038.
FT   VARIANT     486    486       D -> G (in NS5).
FT                                /FTId=VAR_037816.
FT   VARIANT     486    486       D -> N (in NS5; has reduced or absent
FT                                kinase activity).
FT                                /FTId=VAR_037817.
FT   VARIANT     491    491       T -> I (in NS5; has reduced or absent
FT                                kinase activity).
FT                                /FTId=VAR_037818.
FT   VARIANT     491    491       T -> R (in NS5).
FT                                /FTId=VAR_037819.
FT   VARIANT     612    612       S -> T (in NS5).
FT                                /FTId=VAR_037820.
FT   VARIANT     613    613       L -> V (in NS5 and LEOPARD syndrome-2;
FT                                shows in vitro greater kinase activity
FT                                and enhanced MAPK1 activation than wild-
FT                                type).
FT                                /FTId=VAR_037821.
FT   MUTAGEN     259    259       S->A: Increased ERK activation.
FT   CONFLICT    240    240       F -> L (in Ref. 6; AAA60247).
FT   CONFLICT    542    542       M -> I (in Ref. 6; AAA60247).
FT   STRAND       57     62
FT   TURN         63     65
FT   STRAND       66     71
FT   HELIX        78     87
FT   TURN         88     90
FT   HELIX        93     95
FT   STRAND       96    102
FT   HELIX       103    105
FT   STRAND      106    112
FT   HELIX       118    121
FT   STRAND      125    130
FT   STRAND      142    144
FT   STRAND      155    159
FT   STRAND      161    164
FT   TURN        166    169
FT   STRAND      177    182
SQ   SEQUENCE   648 AA;  73052 MW;  EF821B5349711BC3 CRC64;
     MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV
     FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS
     LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV
     PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF
     NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL
     SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF
     GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV
     TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL
     TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE
     LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP
     QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF
//
